Kineta Director Boosts Stake by 18,500 Shares Ahead of TuHURA Merger

Rhea-AI Filing Summary

Director Marion R. Foote of Kineta reported multiple transactions on June 23-25, 2025:

• Exercised 12,500 stock options at $0.611 per share
• Disposed of 4,706 shares at $0.26 per share through tax withholding (F code)
• Received 6,000 shares as new grant at $0 cost

These transactions were part of changes related to the merger agreement between Kineta and TuHURA Biosciences. Per the Optionholder Treatment Agreement dated June 16, 2025, and following stockholder approval on June 23, 2025, the director's options under the 2022 Equity Incentive Plan became fully vested.

Following all transactions, Foote directly owns 165,156 shares of Kineta common stock. The exercised stock options, which had an expiration date of September 3, 2034, have been fully utilized, leaving a balance of 0 derivative securities.

Insider Trade Summary

12,500 shares exercised/converted

Exercise 4 txns

Insider Foote Marion R

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	6,000	$0.00	$0.00
Exercise	Stock Option (Right to Buy)	12,500	$0.00	$0.00
Exercise	Common Stock	12,500	$0.611	$8K
Exercise Price or Tax Liability	Common Stock	4,706	$0.26	$1K

Holdings After Transaction: Stock Option (Right to Buy) — 0 contracts (Direct); Common Stock — 165,156 shares (Direct)

Footnotes (1)

1. F1. Pursuant to the terms of (i) the Optionholder Treatment Agreement, dated June 16, 2025, by and between Kineta, Inc. (the "Company") and the Reporting Person, and (ii) the Agreement and Plan of Merger, dated as of December 11, 2024, by and among the Company, TuHURA Biosciences, Inc., a Nevada corporation ("TuHURA"), Hura Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of TuHURA, Hura Merger Sub II, a Delaware limited liability company and a wholly owned subsidiary of TuHURA, and Craig Philips, as representative of the stockholders of the Company, and as amended by that certain First Amendment to Agreement and Plan of Merger, dated May 5, 2025, as approved by the Company's stockholders at the Special Meeting of Stockholders held on June 23, 2025, the options granted to the Reporting Person under the 2022 Equity Incentive Plan became fully vested on June 23, 2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider trading activity occurred at Kineta (KA) on June 23, 2025?

On June 23, 2025, Director Marion R. Foote exercised 12,500 stock options at $0.611 per share and disposed of 4,706 shares at $0.26 per share. Following these transactions, Foote held 159,156 shares directly.

How many shares does Marion Foote own of Kineta (KA) after all reported transactions?

After all reported transactions, including the June 25, 2025 acquisition of 6,000 shares, Marion Foote owns 165,156 shares of Kineta (KA) directly.

What was the exercise price of Kineta (KA) stock options exercised by Marion Foote?

Marion Foote exercised stock options with an exercise price of $0.611 per share. These options were originally set to expire on September 3, 2034, but were exercised early on June 23, 2025.

Why did Kineta (KA) director Marion Foote's stock options vest early?

The stock options vested early on June 23, 2025, pursuant to an Optionholder Treatment Agreement dated June 16, 2025, and a merger agreement with TuHURA Biosciences, Inc. This was approved by stockholders at a Special Meeting held on June 23, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/25/2025 - 09:52 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Foote Marion R

(Last) (First) (Middle)

C/O KINETA, INC.

7683 SE 27TH STREET, SUITE 481

(Street)

MERCER ISLAND WA 98040

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
KINETA, INC./DE [ KANT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/23/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/23/2025		M		12,500	A	$0.611	163,862	D
Common Stock	06/23/2025		F		4,706	D	$0.26	159,156	D
Common Stock	06/25/2025		A		6,000	A	$0	165,156	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$0.611	06/23/2025		M			12,500	(1)	09/03/2034	Common Stock	12,500	$0	0	D

Explanation of Responses:

1. Pursuant to the terms of (i) the Optionholder Treatment Agreement, dated June 16, 2025, by and between Kineta, Inc. (the "Company") and the Reporting Person, and (ii) the Agreement and Plan of Merger, dated as of December 11, 2024, by and among the Company, TuHURA Biosciences, Inc., a Nevada corporation ("TuHURA"), Hura Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of TuHURA, Hura Merger Sub II, a Delaware limited liability company and a wholly owned subsidiary of TuHURA, and Craig Philips, as representative of the stockholders of the Company, and as amended by that certain First Amendment to Agreement and Plan of Merger, dated May 5, 2025, as approved by the Company's stockholders at the Special Meeting of Stockholders held on June 23, 2025, the options granted to the Reporting Person under the 2022 Equity Incentive Plan became fully vested on June 23, 2025.

	/s/ Nanette Agustines, as Attorney-in-Fact	06/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.